SiliCycle obtains its cannabis processing license from Health Canada

Quebec City, August 5, 2020 – SiliCycle’s management is pleased to have taken another step toward commercializing purified extracts of various cannabinoids with the issuance of its cannabis processing license by Health Canada. The Quebec City-based company can now move forward with processing hemp and cannabis biomass to produce pure, high-quality extracts.

The authorization granted by Health Canada allows SiliCycle to begin production at its new plant in the Quebec Metropolitan Technology Park, where construction was completed in early 2020. More than 22 million $ were invested in construction and equipment acquisition costs related to the implementation of extraction, purification, and packaging processes—which can now be utilized by the company, which is celebrating its 25th anniversary in 2020, and its subsidiary PurCann Pharma, which specializes in this field.

«There is certainly a boom in cannabinoid production, but the focus is particularly on the ability to offer these substances in their pure or standardized form so they can be incorporated into other products. This is precisely where we stand out, with processes that allow us to standardize natural mixtures to achieve the desired quantities and proportions in a stable and reproducible manner, despite variations in these molecules within plants. »This is how we can guarantee our customers the expected effects—an essential condition for commercial success,” says SiliCycle President Hugo St-Laurent.

The new plant has a processing capacity of over 100,000 kg per year, giving SiliCycle the tools to produce thousands of kilograms of extracts at various purity levels to meet its customers’ needs. The facility also features units for preparing finished products—including tinctures, sprays, and more—to meet customer needs, which is why it obtained the necessary authorization from Health Canada for its processing license.

«We are ready to apply all the expertise we have gained in the pharmaceutical field to ensure that our products meet very high standards of quality and reproducibility. Our scientific approach is rigorous and proven; combined with the quality of our new facilities and the presence of high-caliber researchers on our team, we are well-positioned to successfully bring our products to market,» said Pierre Plante, Vice President – Operations at PurCann Pharma.

About SiliCycle Inc.

SiliCycle Inc. is a company that was founded in 1995 in Quebec City. It is a global leader in the development, manufacture, and marketing of specialized products for the pharmaceutical industry. As a technical expert in chemistry, SiliCycle sells its solutions for the extraction and purification of target molecules and in silica chemistry in 90 countries. SiliCycle’s expertise is sought after by everyone from large-scale industrial manufacturers to analytical laboratories at pharmaceutical, cosmetics, nutraceutical, and food companies worldwide that use CRO/CMO products and services. Its scope of services includes, among others:

• Aqueous or organic extraction of various molecules from different types of biomass
• Custom purification solutions from the laboratory to industrial scale
• Development of analytical methods to achieve the desired levels of purity
• Synthesis of molecules of interest
• Production of active ingredients such as omega-3s, polyphenols, and CBD/THC molecules

About PurCann Pharma

PurCann Pharma specializes in the production and marketing of cannabinoid-rich extracts derived from hemp and cannabis grown in Canada. A significant portion of this biomass is certified organic. The purified and standardized extracts, rich in CBD and/or THC, are sold in bulk or as finished products, such as tinctures, capsules, and vaporizers. PurCann Pharma also offers R&D, extraction, purification, and packaging services.